PDGFRB and plasma cell myeloma: Moreover, the expression level of PDGFR-β is closely associated with MM angiogenesis and clinical stage [16], indicating that PDGFR-β could serve well as the therapeutic target for the dual-targeting strategy for myeloma treatment.